About the Company
We do not have any company description for Replimune Group, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Replimune Group, Inc.
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit ...
Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection Of Melanoma Drug Hagens Berman
A securities class action lawsuit, styled Jboor v. Replimune Group, Inc., et al., No. 1:25-cv-12085 (D. Mass.), has been filed and seeks to represent investors who purchased or otherwise acquired ...
REPL Investor Alert: Contact Kessler Topaz Meltzer & Check, LLP About the Securities Fraud Class Action Lawsuit Filed Against Replimune Group, Inc. (REPL)
CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered Replimune losses, you mayCLICK HERE or copy and paste the following link into your browser: ...
Replimune Shares Slide as FDA Dispute Over Cancer Drug Approval Comes to Light
Shares of Replimune Group Inc. (NASDAQ:REPL) plunged 36% in premarket trading after a report revealed new details about the ...
Replimune Group, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before ...
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL).
REPL Stock Nearly Doubled In Value Today: What's Going On?
Shares of Replimune Group Inc. (REPL) were in the retail spotlight on Wednesday after the stock nearly doubled in value. BMO Capital expects the stock to witness a meaningful rally following the exit ...
Replimune Group, Inc. Stockholders With Large Losses Should Contact ...
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer.
Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL ...
Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd PR Newswire NEW YORK, Aug. 4, 2025 ...
REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT Bernstein ...
REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Replimune Group, Inc. Investors of Upcoming Deadline Provided by GlobeNewswireAug 4, 2025, 12:30:00 PM ...
REPL STOCK NEWS: BFA Law is Investigating Replimune Group, Inc. for ...
NEW YORK, NY / ACCESS Newswire / July 23, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Replimune Group, Inc. (NASDAQ:REPL) for potential violations ...
Replimune Group, Inc. Grants Inducement Equity Awards to New ... - Nasdaq
Replimune Group, Inc., a clinical stage biotechnology company based in Woburn, Massachusetts, announced the granting of inducement equity awards to 10 newly hired non-executive employees as part ...
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm
Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) ...
Similar Companies
Loading the latest forecasts...